Antibacterial agents for treating urinary tract infections, their preparation methods and applications

Abstract

The present invention belongs to the technical field of antibacterial products, and particularly relates to an antibacterial agent for treating urinary tract infections, a preparation method thereof, and an application thereof. The antibacterial agent for treating urinary tract infections according to the present invention is composed of chlorhexidine and a calcium solution, and the mass ratio of chlorhexidine to the calcium solution is 0.4 - 0.7:100, and the concentration of the calcium solution is 0.05 g / 100 mL - 0.5 g / 100 mL. The antibacterial agent for treating urinary tract infections prepared by the present invention can treat Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Bacillus subtilis, and in particular, can treat methicillin-resistant Staphylococcus aureus, thereby treating infections caused by the above-mentioned bacteria.

Description

Technical Field

[0001] The present invention belongs to the technical field of antibacterial products, and particularly relates to an antibacterial agent for treating urinary tract infections, its preparation method and application. Background Art

[0002] Urinary tract infection refers to an infectious disease caused by the abnormal reproduction of pathogens in the urinary tract. The most common pathogens of urinary tract infection are bacteria, among which Escherichia coli is the main pathogenic bacterium, and Proteus, Klebsiella, Staphylococcus and other bacteria are also common bacteria causing urinary tract infection. In addition to bacteria, fungi, viruses, chlamydia, mycoplasma, etc. may also cause urinary tract infection. Fungal urinary tract infection usually occurs in patients with long-term use of antibiotics, low immune function or indwelling catheters. Urinary tract infection brings many inconveniences to the daily life of patients and seriously affects the quality of life of patients. Therefore, the treatment of urinary tract infection is of great significance.

[0003] At present, the main drugs for treating urinary tract infections are antibacterial agents. Antibacterial drugs include β-lactams, such as penicillins, cephalosporins, etc., which play an antibacterial role by inhibiting the synthesis of bacterial cell walls; they also include quinolones, which inhibit bacterial DNA gyrase and topoisomerase IV to hinder DNA replication and thus have antibacterial effects, and have good antibacterial activity against Gram-negative bacteria and some Gram-positive bacteria; they also include sulfonamides, whose mechanism of action is to inhibit the growth and reproduction of bacteria by interfering with the folic acid metabolism of bacteria. The above antibacterial agents have the advantages of quick effect and broad antibacterial spectrum. However, if too many antibacterial agents are used, some patients will develop drug resistance, so it is necessary to continue to develop new antibacterial agents. Summary of the Invention

[0004] In order to solve the above technical problems, the present invention provides an antibacterial agent for treating urinary tract infections, its preparation method and application.

[0005] The object of the present invention is to provide an antibacterial agent for treating urinary tract infections, which is composed of chlorhexidine and calcium liquid, and the mass ratio of chlorhexidine to calcium liquid is 0.4 - 0.7:100, and the concentration of calcium liquid is 0.05g / 100mL - 0.5g / 100mL.

[0006] Calcium in the calcium liquid is used to regulate cell metabolic activities, enhance the antibacterial ability of chlorhexidine, and reduce the drug resistance of drug-resistant bacteria to chlorhexidine. The antibacterial agent for treating urinary tract infections of the present invention is suitable for inhibiting at least one of Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa and Bacillus subtilis. The antibacterial agent of the present invention is also used to inhibit methicillin-resistant Staphylococcus aureus resistant to chlorhexidine, where methicillin-resistant Staphylococcus aureus is the MRSA strain.

[0007] Preferably, for the above antibacterial agent for treating urinary tract infections, the calcium liquid is calcium gluconate liquid or calcium citrate liquid. Besides containing calcium, these two liquids are organic calcium, and their solubility and absorbability are superior to those of inorganic calcium such as calcium carbonate.

[0008] Preferably, for the above antibacterial agent for treating urinary tract infections, the concentration of the calcium gluconate liquid is 0.06 g / 100 mL to 0.5 g / 100 mL.

[0009] Preferably, for the above antibacterial agent for treating urinary tract infections, the concentration of the calcium citrate liquid is 0.05 g / 100 mL to 0.06 g / 100 mL.

[0010] Preferably, for the above antibacterial agent for treating urinary tract infections, the solvent of the calcium liquid is sterile water.

[0011] The present invention provides a preparation method of the above antibacterial agent for treating urinary tract infections, including: preparing chlorhexidine and calcium liquid according to the described mass ratio, and mixing them to obtain the antibacterial agent for treating urinary tract infections.

[0012] The present invention provides an application of the above antibacterial agent for treating urinary tract infections. The application refers to mixing the antibacterial agent for treating urinary tract infections with pharmaceutically acceptable excipients to prepare an antibacterial liquid medicine.

[0013] Preferably, for the application of the above antibacterial agent for treating urinary tract infections, the antibacterial liquid medicine is an external lotion.

[0014] Preferably, the excipients corresponding to the external lotion include at least one of (a) to (d):

[0015] (a) Buffer, for example, the buffer is a citric acid - sodium citrate buffer system with a pH of 4.5 to 8.0, which helps to reduce the irritation to the urethral and bladder mucosa. A suitable pH environment is also beneficial to the activity of chlorhexidine and calcium liquid.

[0016] (b) Surfactant, for example, sodium lauryl polyether sulfate, which has good cleaning and emulsifying effects.

[0017] (c) Humectant, for example, glycerol, which can absorb moisture in the surrounding environment and keep the mucosa in a moist state.

[0018] (d) Preservative, for example, potassium sorbate, which is used to prevent the external lotion from being contaminated during storage and use.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The antibacterial agent for treating urinary tract infections provided by the present invention is composed of chlorhexidine and calcium liquid. The mass ratio of chlorhexidine to calcium liquid is 0.4 - 0.7:100, and the concentration of calcium liquid is 0.05 g / 100 mL - 0.5 g / 100 mL. The present invention achieves the purpose of treating urinary tract infections by inhibiting at least one of Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Bacillus subtilis. In particular, it has a good antibacterial effect on methicillin-resistant Staphylococcus aureus and has a wide application prospect. In addition, by utilizing the antibacterial effect of the antibacterial agent for treating urinary tract infections of the present invention, the survival time of these pathogenic bacteria in the environment can be reduced, the transmission risk of pathogenic bacteria can be lowered, and susceptible populations can be protected.

[0021] The present invention also provides an application of an antibacterial agent for urinary tract infections in the preparation of an external lotion. The external lotion has at least the following advantages: (1) It can remove dirt and eliminate odors, and can keep the cleaned part clean; (2) It can prevent and treat urinary tract infections and relieve inflammatory reactions; (3) It can relieve discomfort such as itching and redness; (4) The usage method is simple, it is a topical medication, and the side effects are small. Description of the Drawings

[0022] Figure 1 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for the control group.

[0023] Figure 2 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 1.

[0024] Figure 3 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 2.

[0025] Figure 4 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 3.

[0026] Figure 5 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 4.

[0027] Figure 6 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 5.

[0028] Figure 7 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 6.

[0029] Figure 8 The antibacterial experiment plate diagram of methicillin-resistant Staphylococcus aureus for experimental group 7.

[0030] Figure 9It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 8.

[0031] Figure 10 It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 9.

[0032] Figure 11 It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 10.

[0033] Figure 12 It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 11.

[0034] Figure 13 It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 12.

[0035] Figure 14 It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 13.

[0036] Figure 15 It is the antibacterial experiment petri dish diagram of methicillin-resistant Staphylococcus aureus in experimental group 14. Detailed implementation method

[0037] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention will be further described below in conjunction with specific embodiments and drawings.

[0038] In the description of the present invention, unless otherwise specified, the reagents used are commercially available, and the methods used are conventional techniques in the art.

[0039] Example 1

[0040] An antibacterial agent for treating urinary tract infections is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0041] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0042] Example 2

[0043] An antibacterial agent for treating urinary tract infections is composed of 0.5 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0044] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.5 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0045] Example 3

[0046] An antibacterial agent for treating urinary tract infections is composed of 0.6 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0047] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.6 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0048] Example 4

[0049] An antibacterial agent for treating urinary tract infections is composed of 0.7 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0050] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.7 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0051] Example 5

[0052] An antibacterial agent for treating urinary tract infections is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.06 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0053] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0054] Example 6

[0055] An antibacterial agent for treating urinary tract infections is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0056] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0057] Example 7

[0058] An antibacterial agent for treating urinary tract infections, consisting of 0.5 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0059] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.5 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0060] Example 8

[0061] An antibacterial agent for treating urinary tract infections, consisting of 0.6 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0062] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.6 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0063] Example 9

[0064] An antibacterial agent for treating urinary tract infections, consisting of 0.7 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0065] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.7 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0066] Example 10

[0067] An antibacterial agent for treating urinary tract infections, consisting of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.1 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0068] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0069] Example 11

[0070] An antibacterial agent for treating urinary tract infections, consisting of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.5 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0071] The preparation method of the antibacterial agent for treating urinary tract infections is as follows: Prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, and mix them to obtain the antibacterial agent for treating urinary tract infections.

[0072] The main differences of the above-mentioned embodiments are shown in Table 1. In Table 1, the conditions of other experimental groups are also set. Among them, the control group is sterile water, the chlorhexidine group is the liquid after chlorhexidine is dispersed in sterile water, the calcium gluconate liquid group is the liquid after calcium gluconate is dispersed in sterile water, and the calcium citrate liquid group is the liquid after calcium citrate is dispersed in sterile water. The differences between Examples 1 to 4 are the mass ratio of chlorhexidine and calcium citrate liquid, in order to explore the influence of different mass ratios of chlorhexidine and calcium citrate liquid on the antibacterial effect. Examples 1 and 5 use different concentrations of calcium citrate liquid, in order to explore the influence of different concentrations of calcium citrate liquid on the antibacterial effect. The differences between Examples 6 to 9 are the mass ratio of chlorhexidine and calcium gluconate liquid, in order to explore the influence of different mass ratios of chlorhexidine and calcium gluconate liquid on the antibacterial effect. Examples 5, 10 and 11 use different concentrations of calcium gluconate liquid, in order to explore the influence of different concentrations of calcium gluconate liquid on the antibacterial effect.

[0073] Table 1 Formulations of different experimental groups

[0074]

[0075] I. Antibacterial experiment on methicillin-resistant Staphylococcus aureus.

[0076] (1) Name of the strain: Methicillin-resistant Staphylococcus aureus.

[0077] (2) Preparation of bacterial suspension

[0078] Material preparation: Activate methicillin-resistant Staphylococcus aureus. At the same time, prepare a sodium chloride solution with a mass fraction of 0.9% and sterilize it to obtain sterile normal saline.

[0079] Operation steps: Pick up the activated strain and place it in a sterile test tube containing sterile normal saline. Use a vortex oscillator to oscillate to evenly disperse the bacteria to form a bacterial suspension. Adjust the concentration of the bacterial suspension with sterile normal saline until the concentration of the bacterial suspension is adjusted to 2.0×10 4 cfu / mL.

[0080] (3) Detection of antibacterial rate

[0081] Detection process: In a laminar flow hood, take the prepared bacterial suspension with a concentration of 2.0×10 4100 μL of the bacterial suspension at cfu / mL was added to 5 mL of the liquid to be tested, and the mixture was evenly mixed to obtain a mixed sample. After 20 minutes, 0.5 mL of the mixed sample was taken and added to the nutrient agar medium at 42 °C. After mixing evenly, it was poured into a petri dish. After the nutrient agar medium solidified, it was cultured at 37 °C for 48 h. After the culture was completed, the number of viable bacterial colonies was counted. The experiment was repeated three times, and the average value of the number of viable bacterial colonies was taken.

[0082] The antibacterial rate was calculated according to the following formula:

[0083] 。

[0084] The test results are shown in Table 2. The antibacterial test plate diagram of methicillin-resistant Staphylococcus aureus is shown in Figures 1 to 15 。

[0085] Table 2 Antibacterial rate of methicillin-resistant Staphylococcus aureus

[0086]

[0087] Methicillin-resistant Staphylococcus aureus is a bacterium with multiple drug resistances, and its harms are mainly reflected in the following aspects.

[0088] (1) Difficult clinical treatment: Methicillin-resistant Staphylococcus aureus is resistant to a variety of commonly used antibiotics including methicillin, and commonly used penicillins and cephalosporins are usually ineffective against it. Antibiotics such as vancomycin and linezolid, which are expensive and have more side effects, need to be used for treatment. Therefore, it is necessary to develop new antibacterial agents against methicillin-resistant Staphylococcus aureus.

[0089] (2) High incidence and high mortality: Methicillin-resistant Staphylococcus aureus can infect people of all ages and various health conditions. Special populations such as inpatients, the elderly, and children have relatively poor resistance. Once infected with methicillin-resistant Staphylococcus aureus, the condition often develops rapidly, leading to higher incidence and mortality. In addition, methicillin-resistant Staphylococcus aureus can cause serious infections such as skin and soft tissue infections, bloodstream infections, pneumonia, osteomyelitis, and endocarditis. Taking bloodstream infection as an example, after the bacteria enter the blood, they will spread to all organs of the body along with the blood circulation, triggering a systemic inflammatory response syndrome, and in severe cases, it can lead to septic shock and multiple organ failure.

[0090] In view of the current resistance of methicillin-resistant Staphylococcus aureus to chlorhexidine, it is necessary to develop products that can improve the resistance to chlorhexidine. The antibacterial agent for treating urinary tract infections provided by the present invention has an inhibitory effect on methicillin-resistant Staphylococcus aureus, reduces the infection symptoms of methicillin-resistant Staphylococcus aureus, can improve the respiratory function, and improves the quality of life of patients.

[0091] II. Antibacterial experiments on other strains.

[0092] (1) Names of strains

[0093] Staphylococcus aureus ATCC6538, Escherichia coli ATCC25922, Candida albicans ATCC10231, Pseudomonas aeruginosa ATCC9027, and Bacillus subtilis ATCC21394.

[0094] (2) Preparation of bacterial suspensions

[0095] Material preparation: Activate Staphylococcus aureus ATCC6538, Escherichia coli ATCC25922, Candida albicans ATCC1023, Pseudomonas aeruginosa ATCC9027, and Bacillus subtilis ATCC21394 respectively. Meanwhile, prepare a sodium chloride solution with a mass fraction of 0.9% and sterilize it to obtain sterile physiological saline.

[0096] Operation steps: Pick the activated strains and place them in sterile test tubes containing sterile physiological saline respectively. Use a vortex oscillator to shake to evenly disperse the bacteria to form a bacterial suspension. Adjust the concentration of the bacterial suspension with sterile physiological saline until the concentration of each strain's bacterial suspension is adjusted to 2.0×10 4 cfu / mL.

[0097] (3) Detection of antibacterial rate

[0098] Detection process: In a laminar flow hood, take 100 μL of the prepared bacterial suspension with a concentration of 2.0×10 4 cfu / mL and add it to 5 mL of the liquid to be tested, mix well to obtain a mixed sample. After 20 min, take 0.5 mL of the mixed sample for gradient dilution, add the diluted and undiluted liquids to the medium at 42°C respectively, mix well and pour into petri dishes. After the medium solidifies, incubate at 35°C. Among them, the media used for Staphylococcus aureus ATCC6538, Escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC9027, and Bacillus subtilis ATCC21394 are nutrient agar media, and the incubation time at 35°C is 48 h. The medium used for Candida albicans ATCC10231 is Sabouraud agar medium, and the incubation time at 35°C is 72 h. After the incubation is completed, count the number of viable bacterial colonies. Repeat the experiment three times and take the average value of the number of viable bacterial colonies.

[0099] The test results are shown in Table 3. The liquids to be tested corresponding to each experimental group in Table 3 refer to Table 1.

[0100] Table 3 Antibacterial rates of other strains

[0101]

[0102] The results in Table 3 show that the antibacterial agents for treating urinary tract infections in Examples 1 to 11 have good inhibitory effects on Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Bacillus subtilis.

[0103] In urinary tract infections, Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Bacillus subtilis are all common pathogenic bacteria. Effectively inhibiting these pathogenic bacteria has at least the following benefits for urinary tract infections.

[0104] (1) Eliminate the source of infection

[0105] The large reproduction of bacteria such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis will damage tissues such as the urinary tract mucosa and cause inflammation. When these bacteria are effectively inhibited, the number of bacteria is greatly reduced and they cannot continue to reproduce in large numbers, thus reducing the direct damage to tissues.

[0106] (2) Alleviate symptoms

[0107] During urinary tract infections, due to the stimulation of pathogenic bacteria, patients often experience symptoms such as frequent urination, urgency, and pain during urination. When these pathogenic bacteria are eliminated, the inflammation of the urinary tract mucosa gradually subsides, the irritation to the bladder and urethra is reduced, and abnormal urination is alleviated. For example, in cystitis caused by Pseudomonas aeruginosa infection, patients have a frequent urge to urinate and experience unbearable pain during urination. After inhibiting the bacteria, the inflammation of the bladder mucosa improves, and the symptoms of frequent urination and pain during urination are alleviated. In some patients with urinary tract infections, it can also cause lower abdominal pain, a feeling of fullness, as well as systemic symptoms such as fever and chills. For example, toxins produced by bacteria such as Staphylococcus aureus will enter the blood and affect the whole body. After inhibiting the bacteria, the production of toxins is reduced, the body's immune response gradually returns to normal, which helps to relieve discomfort in the lower abdomen, reduce body temperature, alleviate systemic symptoms, and make the patient's body return to a comfortable state.

[0108] (3) Prevent complications

[0109] If the infection caused by Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis is not effectively controlled, the bacteria may ascend to infect the kidneys and cause serious diseases such as pyelonephritis. For example, when Escherichia coli and other pathogens infect the kidneys, they will damage kidney tissue and affect kidney function. Timely inhibition of these pathogens can effectively prevent the spread of infection to the kidneys, protect the normal structure and function of the kidneys, and prevent the occurrence of serious complications such as renal dysfunction and renal abscesses. When the bacteria in the blood multiply in large numbers, sepsis may occur, which is a serious and potentially life-threatening disease. Staphylococcus aureus, Pseudomonas aeruginosa, etc. are highly pathogenic. If they are not suppressed in time during urinary tract infections, they may enter the blood, and in severe cases, they may induce sepsis. Therefore, inhibiting these pathogens can significantly reduce the risk of sepsis and protect the lives of patients.

[0110] In summary, the antibacterial agent for treating urinary tract infection provided by the present invention can effectively inhibit Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis, especially can inhibit methicillin-resistant Staphylococcus aureus, thereby effectively preventing and treating urinary tract infection.

[0111] It should be noted that when the present invention involves a numerical range, it should be understood that the two endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as those in the embodiments, in order to avoid redundancy, the present invention describes a preferred embodiment. Although the preferred embodiments of the present invention have been described, once those skilled in the art know the basic inventive concept, they can make other changes and modifications to these embodiments, and these changes and modifications all fall within the scope of the present invention.

[0112] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. If these modifications and variations of the present invention fall within the scope of the equivalent technology of the present invention, the present invention is also intended to include these modifications and variations.

Claims

1. Use of calcium liquid and chlorhexidine in the preparation of an antibacterial agent, characterized in that, The antibacterial agent is prepared from chlorhexidine and calcium liquid in a mass ratio of 0.4 - 0.7:100, and the concentration of the calcium liquid is 0.05 g / 100 mL - 0.5 g / 100 mL; The antibacterial agent inhibits methicillin-resistant Staphylococcus aureus; The calcium liquid is calcium gluconate liquid or calcium citrate liquid.

2. The use of the calcium liquid and chlorhexidine according to claim 1 in the preparation of an antibacterial agent, characterized in that, The concentration of the calcium gluconate liquid is 0.06 g / 100 mL - 0.5 g / 100 mL.

3. The use of the calcium liquid and chlorhexidine according to claim 1 in the preparation of an antibacterial agent, characterized in that, The concentration of the calcium citrate liquid is 0.05 g / 100 mL - 0.06 g / 100 mL.

4. Use of the calcium liquid and chlorhexidine according to claim 1 in the preparation of an antibacterial agent, characterized in that, The solvent of the calcium liquid is sterile water.

5. Use of the calcium liquid and chlorhexidine according to claim 1 in the preparation of an antibacterial agent, characterized in that, The preparation method of the antibacterial agent is: prepare the chlorhexidine and the calcium liquid according to the mass ratio, and mix them to obtain the antibacterial agent.

6. The use of the calcium liquid and chlorhexidine according to claim 1 in the preparation of an antibacterial agent, characterized in that, Mix the antibacterial agent with pharmaceutically acceptable excipients to prepare a medicinal liquid for antibacterial use.

7. Use of the calcium liquid and chlorhexidine according to claim 6 in the preparation of an antibacterial agent, characterized in that, The medicinal liquid is an external lotion.

Images